Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246972 · ClinicalTrials.gov registry record · Phase 2
BraveMind: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02246972 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 15 participants.
The verdict
NCT02246972, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The proposed study is designed to test the clinical efficacy of the BRAVEMIND military sexual trauma (MST) system in an initial feasibility and wait list clinical trial of 45 users. The following hypotheses will be tested: 1. Virtual Reality Exposure Therapy (VRET) will be safely deliverable to persons with posttraumatic stress disorder (PTSD) due to MST as evidenced by treatment dropout rates that are similar to existing Prolonged Exposure (PE) therapy delivered in military samples (20-40%) and by the absence of any critical incidents. 2. Participants in the VRET group will show statistically and clinically meaningful reductions in PTSD and depression (PTSD Checklist-Military (PCL-M), Clinician Administered PTSD Scale (CAPS), and Patient Health Questionnaire (PHQ-9) scores and psychophysiological measures) following treatment. 3. Participants in the VRET group will show statistically and clinically meaningful reductions in PTSD and depression (PCL-M, CAPS, PHQ-9 scores and psychophysiological measures) compared to wait-list results.
Interventions
- BEHAVIORAL Virtual Reality Exposure Therapy (VRET)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02246972
The ClinicalTrials.gov registry entry for NCT02246972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Virtual Reality Exposure Therapy (VRET) is the first listed.
NCT02246972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02246972 about?
NCT02246972 is a clinical study titled "BraveMind: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy". The proposed study is designed to test the clinical efficacy of the BRAVEMIND military sexual trauma (MST) system in an initial feasibility and wait list clinical trial of 45 users. The following hypotheses will be tested: 1. Virtual Reality Exposure Therapy (VRET) will be safely deliverable to pe...
What is the current status of trial NCT02246972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-05. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02246972?
The interventions under investigation include: Virtual Reality Exposure Therapy (VRET) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02246972?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.